Abstract Depression and anxiety are disabling and high incidence mental disorders characterized by phenotypic heterogeneity. Currently available treatments show severe limitations. Thus, there is an urgent need for effective treatments in this population. In the search for novel rapid-acting antidepressants, the psychedelic psilocybin has emerged as a promising therapy in several clinical...
The full therapeutic potential of serotonergic psychedelics (SP) in treating neuropsychiatric disorders, such as depression and schizophrenia, is limited by possible adverse effects, including perceptual disturbances and psychosis, which require administration in controlled clinical environments. This study investigates the synergistic benefits of combining psilocybin (PSIL) with...
Substituted tryptamines with selective 5-HT2A/2C activity demonstrate therapeutic promise without psychedelic effects. Two recent patent applications describe nonhallucinogenic analogs for metabolic and neuropsychiatric disorders. These agents exhibit optimized receptor selectivity, metabolic synergy, and neuroplastic potential, offering a novel chemical framework for multimodal treatment...
The Abhidhamma, a classical Buddhist doctrine, offers a profound understanding of cognitive processing and sensory perception, concepts formulated over 2700 years ago and recently reflected in modern neuroscience. It presents a sophisticated cognitive model in which consciousness (citta), mental factors (cetasika), and materiality (rūpa) co-arise and function in a causally interdependent...
Background/Objectives: Depression ranks among the most prevalent mental health conditions globally, marked by a variety of symptoms that frequently cause significant emotional distress and impairment in individuals, alongside a high recurrence rate. The predominant approach to treating depression revolves around monoamine theory, utilizing SSRIs and SNRIs, with Esketamine emerging as a...
Objective.Disorders of consciousness (DoC) remain a significant challenge in neurology, with traditional brain stimulation therapies showing limited and inconsistent efficacy across patients. This study presents a novel computational approach grounded in neural field theory for constructing personalized stimulus signals designed to induce healthy-like neural activity patterns in individuals...
Ketamine, an N-methyl-D-aspartate receptor antagonist, has demonstrated rapid antidepressant effects at sub-anesthetic doses, making it a promising candidate for treatment-resistant mood disorders, anxiety, post-traumatic stress disorder, suicidality, and recently, eating disorders (EDs). However, its effects are transient, and ketamine-assisted psychotherapy (KAP) has emerged as a method to...
Abstract Background Opioid abstinence induces persistent emotional disturbances and widespread neuroplastic changes, in areas of the brain including the hippocampus. Although ketamine and its metabolite ( 2R,6R )-hydroxynorketamine (HNK) show potential in reversing opioid abstinence-related deficits in rodents, the molecular mechanisms underlying their efficacy remain poorly understood. Methods...
Millions worldwide suffer from chronic pain, a complex condition often accompanied by depression and anxiety, highlighting the urgent need for innovative treatments. Classic psychedelics, including psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT), primarily act on serotonin 5-HT2A receptors and have emerged as potential modulators of pain perception and mood...
However, Yoga is widely regarded as a very old mind body practice with the potential to lead to mental health and wellbeing. In this study, the supplement of Yoga to pharmacotherapy in the management of mental health disorders was investigated. Although no pharmacological interventions still remain the bedrock of treatment for disease such as depression, anxiety or stress related, Yoga has a...